Seagen Inc.
SGENDrugs in Pipeline
40
Phase 3 Programs
13
Upcoming Catalysts
12
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
12 upcoming, 0 past
Adcetris
Brentuximab Vedotin
Hodgkin Lymphoma
tucatinib
Gastric Adenocarcinoma
brentuximab vedotin
Lymphoma, B-Cell
Padcev
Enfortumab Vedotin
Urothelial Cancer
levoleucovorin
Colorectal Neoplasms
Bleomycin
Hodgkin Lymphoma
vincristine
Anaplastic Large-Cell Lymphoma
leucovorin
Colorectal Carcinoma
Vinblastine
Hodgkin Lymphoma
Enfortumab vedotin (EV)
Bladder Cancer
Enfortumab Vedotin
Renal Pelvis and Ureter Urothelial Carcinoma
sigvotatug vedotin
Carcinoma, Non-Small-Cell Lung
Haematopoietic growth factor
Hodgkin Lymphoma
disitamab vedotin
Breast Neoplasms
tisotumab vedotin
Ovarian Cancer
SGN-30
Large Cell Lymphoma
Adriamycin, vinblastine, and dacarbazine
Hodgkin Lymphoma
Doxil
Breast Cancer
brentuximab vedotin (SGN-35)
Hodgkin's Lymphoma
Doxorubicin Hydrochloride
Hodgkin Lymphoma
Tucatinib Oral Tablet
Leptomeningeal Metastasis
Alpelisib
HER2-positive Metastatic Breast Cancer
Pertuzumab
Metastatic Breast Cancer With a Isolated Brain Progression
Sunitinib
Lymphoma, Non-Hodgkin
CHEP
Lymphoma
Dacarbazine(R)
Stage II Childhood Hodgkin Lymphoma
Adriamycin
Hodgkin Lymphoma
SGN-35
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
Tukysa
Tucatinib
HER2+ Breast Cancer
SGN-40
Lymphoma, Large B-Cell, Diffuse
SGN-30 (monoclonal antibody)
Hodgkin Disease
SGN-15 (cBR96-doxorubicin immunoconjugate)
Prostatic Neoplasms
SGN-15
Carcinoma, Non-Small-Cell Lung
SGN-30 (anti-CD30 mAb)
Anaplastic Large-Cell Lymphoma
SEA-CD40
Melanoma
Tisotumab Vedotin (HuMax-TF-ADC)
Ovary Cancer
SGN-40 (anti-huCD40 mAb)
Leukemia, Lymphocytic, Chronic
Lintuzumab (SGN-33)
Acute Myeloid Leukemia
ladiratuzumab vedotin
Triple Negative Breast Neoplasms
SGN-15, Docetaxel
Non-Small Cell Lung Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adcetris Brentuximab Vedotin | Approved | Hodgkin Lymphoma | Orphan | - |
tucatinib | Phase 3 | Gastric Adenocarcinoma | - | Patent 2038 |
brentuximab vedotin | Phase 3 | Lymphoma, B-Cell | - | - |
Padcev Enfortumab Vedotin | Phase 3 | Urothelial Cancer | Fast TrackBreakthrough | - |
levoleucovorin | Phase 3 | Colorectal Neoplasms | - | - |
Bleomycin | Phase 3 | Hodgkin Lymphoma | - | - |
vincristine | Phase 3 | Anaplastic Large-Cell Lymphoma | - | - |
leucovorin | Phase 3 | Colorectal Carcinoma | - | - |
Vinblastine | Phase 3 | Hodgkin Lymphoma | - | - |
Enfortumab vedotin (EV) | Phase 3 | Bladder Cancer | - | - |
Enfortumab Vedotin | Phase 3 | Renal Pelvis and Ureter Urothelial Carcinoma | - | - |
sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Haematopoietic growth factor | Phase 3 | Hodgkin Lymphoma | - | - |
disitamab vedotin | Phase 3 | Breast Neoplasms | - | - |
tisotumab vedotin | Phase 2 | Ovarian Cancer | - | - |
SGN-30 | Phase 2 | Large Cell Lymphoma | - | - |
Adriamycin, vinblastine, and dacarbazine | Phase 2 | Hodgkin Lymphoma | - | - |
Doxil | Phase 2 | Breast Cancer | - | - |
brentuximab vedotin (SGN-35) | Phase 2 | Hodgkin's Lymphoma | - | - |
Doxorubicin Hydrochloride | Phase 2 | Hodgkin Lymphoma | - | - |
Tucatinib Oral Tablet | Phase 2 | Leptomeningeal Metastasis | - | - |
Alpelisib | Phase 2 | HER2-positive Metastatic Breast Cancer | - | - |
Pertuzumab | Phase 2 | Metastatic Breast Cancer With a Isolated Brain Progression | - | - |
Sunitinib | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
CHEP | Phase 2 | Lymphoma | - | - |
Dacarbazine(R) | Phase 2 | Stage II Childhood Hodgkin Lymphoma | - | - |
Adriamycin | Phase 2 | Hodgkin Lymphoma | - | - |
SGN-35 | Phase 2 | CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma | - | - |
Tukysa Tucatinib | Phase 2 | HER2+ Breast Cancer | Fast TrackBreakthrough | Patent 2038 |
SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
SGN-30 (monoclonal antibody) | Phase 2 | Hodgkin Disease | - | - |
SGN-15 (cBR96-doxorubicin immunoconjugate) | Phase 2 | Prostatic Neoplasms | - | - |
SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SGN-30 (anti-CD30 mAb) | Phase 2 | Anaplastic Large-Cell Lymphoma | - | - |
SEA-CD40 | Phase 2 | Melanoma | - | - |
Tisotumab Vedotin (HuMax-TF-ADC) | Phase 2 | Ovary Cancer | - | - |
SGN-40 (anti-huCD40 mAb) | Phase 2 | Leukemia, Lymphocytic, Chronic | - | - |
Lintuzumab (SGN-33) | Phase 2 | Acute Myeloid Leukemia | - | - |
ladiratuzumab vedotin | Phase 2 | Triple Negative Breast Neoplasms | - | - |
SGN-15, Docetaxel | Phase 2 | Non-Small Cell Lung Carcinoma | - | Patent 2036 |
Urothelial Cancer
1 drug in this indication
HER2+ Breast Cancer
1 drug in this indication
Triple Negative Breast Neoplasms
1 drug in this indication
Hodgkin Lymphoma
1 drug in this indication
Leukemia, Lymphocytic, Chronic
1 drug in this indication
Lymphoma, Large B-Cell, Diffuse
1 drug in this indication
Hodgkin Disease
1 drug in this indication
Prostatic Neoplasms
1 drug in this indication
Gastric Adenocarcinoma
1 drug in this indication
Large Cell Lymphoma
1 drug in this indication
Lymphoma, B-Cell
1 drug in this indication
Ovary Cancer
1 drug in this indication
Non-Small Cell Lung Carcinoma
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Melanoma
1 drug in this indication
Acute Myeloid Leukemia
1 drug in this indication
Anaplastic Large-Cell Lymphoma
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Disease, Hodgkin
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Seagen Inc.'s drug pipeline?→
CatalystAlert tracks 40 drug candidates in Seagen Inc.'s (SGEN) pipeline across Phase 3, Phase 2, Approved. Its lead program is tucatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seagen Inc.'s next FDA catalyst?→
Seagen Inc.'s (SGEN) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGEN biotech catalysts?→
Add SGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seagen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.